Thousands of patients are stuck on waiting lists as hospitals struggle to ramp up infusion centers and monitoring processes for Leqembi, while neurologists grapple with workforce and capacity constraints.
Pfizer says it expects to restart production at its North Carolina plant by the beginning of the fourth quarter of 2023 as it seeks to repair tornado damage to one of the world's largest sterile injectable drug facilities.
The drugmaker's ability to salvage production equipment and other essential materials could mitigate what experts feared would be a major blow to an already strained system as the United States grapples with existing drug shortages.